Kangpu Completes Phase I Trial of Cancer Immunomodulator

Kangpu
Published on: October 11, 2019
Author: Amy Liu

Kangpu Biopharma of Shanghai completed a first-in-human US Phase I trial of KPG-818, a small molecule immunomodulator based on the CRBN E3 ubiquitin ligase complex. Kangpu expects KPG-818 will be an effective treatment for systemic lupus erythematosus (SLE) and hematological malignancies. In the Phase I trial, which was conducted in healthy participants, KPG-818 did not show any safety or tolerability problems. Kangpu, formed by returnees, is developing novel small molecule drugs for cancer, autoimmune and inflammatory disorders.

Source: China Biotoday

Biotechnology Healthcare Services Pharmaceutical